Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

The researchers loaded the platform with two pairs of drugs approved by the FDA: BRAF and MEK inhibitors used to treat melanoma (skin cancer) with a BRAF gene mutation (present in 50% of melanoma ...

MIAMI - Pasithea Therapeutics Corp. (NASDAQ: KTTA), a micro-cap biotech firm with a market capitalization of $2.63 million focusing on developing treatments for central nervous system disorders and ...

For instance, a study on the use of BRAF-MEK inhibitors in patients with papillary craniopharyngiomas demonstrated promising results, with a significant percentage of patients showing a durable ...

Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1 clinical trial of ...

The following is a summary of “Anakinra improves retention rate of targeted treatments in Erdheim-Chester disease,” published ...

KRAS mutation in endothelial cells activates the MEK/ERK pathway, but has no direct effect on PI3k. Subsequently, KRAS/BRAF activates the Notch pathway or TGFb/BMP pathway through the MEK/ERK ...

NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (NCT06299839). About Pasithea Therapeutics Corp. Pasithea is a biotechnology company focused on the discovery, research and ...

They include RAF inhibitors, such as sorafenib and vemurafenib, or MEK inhibitors such as selumetinib (AZD6244). Since trials investigating the potential use of anti-BRAF agents in the management ...

The BRAF Inhibitors market is expected to grow significantly in the coming years. This is due to the increasing number of patients being diagnosed with cancer, rise in biomarker testing rates, the ...

NF1 or RAF mutation or patients who have failed BRAF/MEK inhibition (NCT06299839). About Pasithea Therapeutics Corp. Pasithea ...